Vaxcyte is a clinical-stage biotechnology company developing novel protein-based vaccines, including advanced pneumococcal conjugate vaccine candidates.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Seth Klarman / Baupost | 64 | New buy | 800,000 | $46,488 | 0.9% |
| Bridgewater | 55 | New buy | 12,903 | $749,793 | 0.0% |
| Report | Date | Stance |
|---|---|---|
| #97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami | 2025-05-28 | WATCH |
| #84 — Market Memo: Healthcare's AI-Powered Trump Card | 2025-02-09 | SHORT |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-20.